Investigating how TIGIT helps protect the heart during cancer immunotherapy
Official title: TIGIT upholds peripheral tolerance in ICI-myocarditis
Funded at Johns Hopkins University · NIH-10995605 · Data updated 2026-11-12
This study is looking at how a protein called TIGIT might help protect the heart from damage caused by cancer treatments known as immune checkpoint inhibitors, which can sometimes lead to heart problems in patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $48,974 |
| NIH project number | 1F31HL175896-01 |
| Project ID | NIH-10995605 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are receiving immune checkpoint inhibitors and are at risk for heart-related side effects.
✕Less likely to help
Patients who are not undergoing cancer treatment or those who do not have a risk of ICI-myocarditis may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called TIGIT in preventing heart damage caused by immune checkpoint inhibitors (ICIs), which are used in cancer treatment. While ICIs can effectively target tumors, they may also trigger harmful immune responses that affect the heart, leading to a serious condition known as ICI-myocarditis. The study will explore how TIGIT signaling interacts with other immune pathways to maintain heart health during cancer therapy. By examining these mechanisms in laboratory models, the research aims to identify potential strategies to mitigate heart-related side effects in cancer patients receiving ICIs.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for protecting the heart in cancer patients undergoing immunotherapy.
How similar studies have gone: Previous studies have shown that targeting immune pathways can effectively reduce adverse effects in cancer treatments, suggesting potential success for this approach.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Jaime, Camille — Johns Hopkins University
- Study coordinator: Jaime, Camille
Related research
Other NIH-funded projects on the same topics.
-
Rapid bedside molecular imaging of heart inflammation with ultrasound
A fast, point-of-care ultrasound test using special contrast bubbles may help doctors quickly see active heart inflammation in people with chest pain or suspected ACS.
-
Muscle-Related Enzyme TRIM55 and Autoimmune Heart Inflammation in Aicardi-Goutieres Syndrome
A new research project studies how a muscle-specific enzyme called TRIM55 drives autoimmune heart inflammation in a genetic syndrome.
-
Targeted CXCR3 blockade to treat immunotherapy-related heart inflammation
A targeted drug approach aims to prevent or lessen heart inflammation caused by immune therapies in cancer patients, using CXCR3-blocking strategies.
-
Viral tricks that disrupt heart cell connections in myocarditis
This grant looks at how a common cold virus (adenovirus) may mess with the heart’s electrical signals and could lead to dangerous arrhythmias in people with myocarditis.
-
Immunologic and Antigenic Drivers of Immune Checkpoint Inhibitor–Associated Heart Inflammation
A doctor-scientist team is studying why cancer patients treated with immune checkpoint drugs sometimes develop dangerous heart inflammation and what immune targets cause it.
-
Understanding how T cells and heart cells talk in a life-threatening heart inflammation from cancer immunotherapy
A doctor–scientist will study how immune T cells interact with heart cells in people treated for cancer who develop dangerous inflammation from immune checkpoint inhibitors.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.